12:00 AM
 | 
Jan 29, 2007
 |  BioCentury  |  Emerging Company Profile

ProtAffin: Gagging inflammation

Instead of pursuing the usual therapeutic approach of interrupting extracellular protein-protein interactions, ProtAffin Biotechnologie AG hopes to develop a new class of protein therapeutics that target carbohydrates found on pro-teoglycan co-receptors located in inflamed tissues. According to the company, the approach provides an alternative mechanism that could succeed in situations where antibodies have failed.

ProtAffin is using its CellJammer technology to engineer chemokines and other molecules to selectively bind specific glycosaminoglycans. GAGs are carbohydrates found on proteoglycans.

"GAGs are expressed ubiquitously on every eukaryotic cell, but they are expressed in specific structures on each cell type. There’s a specific GAG sequence for every cell, tissue and pathology," said CSO Andreas Kungl.

ProtAffin is targeting GAGs lodged in the cell membrane of inflamed endothelium. The company is focused on inflammation, where chemokine-GAG interactions are implicated.

Chemokines induce the...

Read the full 671 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >